2023
Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy
Hertz D, Tofthagen C, Rossi E, Bernasconi D, Lim J, Carlson M, Sheffield K, Nekhlyudov L, Grech L, Von Ah D, Mayo S, Ruddy K, Chan A, Alberti P, Lustberg M, Tanay M. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy. Supportive Care In Cancer 2023, 32: 48. PMID: 38129602, DOI: 10.1007/s00520-023-08209-0.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyNeurotoxic chemotherapy treatmentChemotherapy treatmentSymptom resolutionPeripheral neuropathySevere chemotherapy-induced peripheral neuropathyCommon reason participantsMethodsA cross-sectional online surveyBetter patient educationCross-sectional online surveyNeurotoxic chemotherapyCIPN symptomsMedian ageMost patientsTreating clinicianLong-term benefitsPatients' perceptionsPatient educationPractice guidelinesTreatment goalsClinicians' understandingTreatment efficacyConclusionsThis surveyPatientsSymptomsBiomechanical effect of neurologic dance training (NDT) for breast cancer survivors with chemotherapy-induced neuropathy: study protocol for a randomized controlled trial and preliminary baseline data
Lantis K, Schnell P, Bland C, Wilder J, Hock K, Vargo C, Glover N, Hackney M, Lustberg M, Worthen-Chaudhari L. Biomechanical effect of neurologic dance training (NDT) for breast cancer survivors with chemotherapy-induced neuropathy: study protocol for a randomized controlled trial and preliminary baseline data. Trials 2023, 24: 564. PMID: 37658464, PMCID: PMC10472642, DOI: 10.1186/s13063-023-07554-z.Peer-Reviewed Original ResearchConceptsChemotherapy-induced neuropathyPhysical activityBackgroundBreast cancerOutcome measuresNon-pharmacologic interventionsBreast cancer survivorsPrimary outcome measureHome exercise interventionQuality of lifeControl intervention groupPreliminary baseline dataPrimary endpointExercise interventionBC survivorsTertiary outcomesCancer survivorsSensorimotor symptomsClinical trialsIntervention groupTwo-armWeek 8Mean changeFall riskPrimary estimandTreatment groupsFemale reproductive health in pediatric, adolescent, and young adult cancer survivors
Hoefgen H, Benoit J, Chan S, Jayasinghe Y, Lustberg M, Pohl V, Saraf A, Schmidt D, Appiah L. Female reproductive health in pediatric, adolescent, and young adult cancer survivors. Pediatric Blood & Cancer 2023, 70: e29170. PMID: 37381166, DOI: 10.1002/pbc.29170.Peer-Reviewed Original ResearchConceptsQuality of lifeGenital graftHost diseaseCancer survivorsLate effectsReproductive healthHematopoietic stem cell transplantCancer treatmentYoung adult cancer survivorsHormone replacement therapyCervical cancer screeningStem cell transplantFemale reproductive healthAdult cancer survivorsLarge cohort studyLikelihood of pregnancyYoung Adult Cancer SurvivorshipAdult cancer survivorshipGynecologic outcomesVaginal injuryCohort studyCell transplantReplacement therapyCancer careCancer screeningWorry and Mindfulness Differentially Impact Symptom Burden Following Treatment Among Breast Cancer Survivors: Findings From a Randomized Crossover Trial
Renna M, Madison A, Peng J, Shrout M, Lustberg M, Ramaswamy B, Wesolowski R, VanDeusen J, Williams N, Sardesai S, Noonan A, Reinbolt R, Stover D, Cherian M, Malarkey W, Andridge R, Kiecolt-Glaser J. Worry and Mindfulness Differentially Impact Symptom Burden Following Treatment Among Breast Cancer Survivors: Findings From a Randomized Crossover Trial. Annals Of Behavioral Medicine 2023, 57: 888-898. PMID: 37335884, PMCID: PMC10498820, DOI: 10.1093/abm/kaad032.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCancer SurvivorsCross-Over StudiesFatigueFemaleHumansMindfulnessPainQuality of LifeSurvivorsConceptsEmotion regulationMemory problemsCognitive tasksBreast cancer survivorsEmotion regulation abilitiesAdaptive emotion regulationEmotion regulation skillsHigher subjective fatigueSubjective memory problemsCancer survivorsCognitive side effectsPain sensitivityRegulation skillsLow mindfulnessCognitive problemsMindfulness QuestionnaireRegulation abilitySubjective fatiguePhysical healthBreast cancer survivorshipCold pain sensitivityObjective ratingsConcentration problemsMindfulnessInflammatory responseMitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
Lustberg M, Kuderer N, Desai A, Bergerot C, Lyman G. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nature Reviews Clinical Oncology 2023, 20: 527-542. PMID: 37231127, PMCID: PMC10211308, DOI: 10.1038/s41571-023-00776-9.Peer-Reviewed Original ResearchConceptsAdverse eventsEvidence-based clinical practice guidelinesChemotherapy-associated adverse eventsNon-pharmacological treatment strategiesAdverse effectsClinical practice guidelinesAdverse treatment effectsCourse of therapyTotality of evidenceQuality of lifeTerms of survivalRisk assessment toolOptimal therapyCancer survivorsRisk factorsOncology practiceTreatment strategiesPractice guidelinesUnderlying biological mechanismsAppropriate managementAnticancer treatmentCancer treatmentEffective interventionsTreatment effectsChemotherapyFramework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN)
Stoller S, Capozza S, Alberti P, Lustberg M, Kleckner I. Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN). Supportive Care In Cancer 2023, 31: 293. PMID: 37086308, DOI: 10.1007/s00520-023-07734-2.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsHumansNeurotoxicity SyndromesPeripheral Nervous System DiseasesPhysical TherapistsQuality of LifeConceptsChemotherapy-induced peripheral neurotoxicityPhysical therapy guidelinesPhysical therapistsPhysical therapyCIPN assessmentPeripheral neurotoxicityOncology teamTherapy guidelinesHome-based exercise prescriptionBurden of chemotherapyManual therapy interventionsClinical practice guidelinesPhysical therapy assessmentLimited effective treatmentsQuality of lifePhysical performance measuresSymptom management researchCIPN treatmentNeurologic symptomsMotor dysfunctionPatient functionExercise prescriptionAerobic trainingChemotherapy agentsPractice guidelinesRetrospective cohort study of scalp cooling in breast cancer patients
Rose L, Schnell P, Radcliff L, Lustberg M, Dulmage B. Retrospective cohort study of scalp cooling in breast cancer patients. Supportive Care In Cancer 2023, 31: 118. PMID: 36645520, DOI: 10.1007/s00520-022-07562-w.Peer-Reviewed Original ResearchConceptsScalp coolingChemotherapy regimenPatient ageInsurance statusRetrospective cohort studyCommon side effectsRetrospective chart reviewNon-white patientsBreast cancer patientsStage of cancerQuality of lifeChart reviewCohort studyWhite patientsPatient's likelihoodChemotherapy infusionCancer patientsTreatment optionsOncology settingBreast cancerPatient decisionSide effectsPatientsTreatment planHealthcare providers
2022
Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Lockwood B, El-Jawahri A, Walker A, Ehrman S, Russell D, Kale S, Gustin J, Bose-Brill S, LeBlanc T, Luger S, Lustberg M, Bhatnagar B. Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy. Journal Of Adolescent And Young Adult Oncology 2022, 12: 592-598. PMID: 36367711, DOI: 10.1089/jayao.2022.0082.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnxietyHumansInduction ChemotherapyLeukemia, Myeloid, AcutePsychological DistressQuality of LifeYoung AdultConceptsYoung adultsHigh-risk AMLUnpredictable illness trajectoriesPatient-reported outcomesHospitalized young adultsHighest post-traumatic stress disorderPost-traumatic stress disorderInduction chemotherapyIntensive chemotherapyUnmet psychological needsClinical trialsIllness trajectoryWeek 2Secondary analysisStress disorderOlder adultsPsychological distressLife disruptionChemotherapyWorse qualityAdultsAMLHigh anxietyAnxietyHospitalization
2021
Supportive Care: Low Cost, High Value.
Popescu RA, Roila F, Arends J, Metro G, Lustberg M. Supportive Care: Low Cost, High Value. American Society Of Clinical Oncology Educational Book 2021, 41: 1-11. PMID: 33830830, DOI: 10.1200/edbk_320041.Peer-Reviewed Original ResearchConceptsQuality of lifePhysical exerciseChemotherapy-induced peripheral neuropathyLarge phase III trialsElectronic patient-reported outcome measuresPatient-reported outcome measuresPersonalization of chemotherapySupportive care unitPhase III trialsSupportive care interventionsCancer-related fatigueMind-body interventionsNonpharmacologic strategiesScrambler therapyGastrointestinal dysmotilityIII trialsOverall survivalSupportive careTreatable causeMuscle trainingPeripheral neuropathyCare unitClinic appointmentsMetabolic derangementsRegular screeningAdverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias
Schnell PM, Lustberg MB, Henry NL. Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias. JNCI Cancer Spectrum 2021, 5: pkab018. PMID: 33842832, PMCID: PMC8023424, DOI: 10.1093/jncics/pkab018.Peer-Reviewed Original ResearchConceptsPatient-perceived benefitsAdverse eventsBrief Pain Inventory-Short FormAromatase Inhibitor–Associated ArthralgiaDuloxetine-treated patientsOriginal primary outcomeDouble-blind trialLow-grade toxicityEffect of duloxetineSubgroup of patientsAverage painComparable patientsAppropriate patientsPrimary outcomeMusculoskeletal symptomsBreast cancerPlaceboDuloxetineSide effectsFunctional assessmentPatientsSecondary analysisFavorable effectTreatmentPerceptions of benefits
2020
Worry and rumination in breast cancer patients: perseveration worsens self-rated health
Renna ME, Rosie Shrout M, Madison AA, Lustberg M, Povoski SP, Agnese DM, Reinbolt RE, Wesolowski R, Williams NO, Ramaswamy B, Sardesai SD, Noonan AM, VanDeusen JB, Malarkey WB, Kiecolt-Glaser JK. Worry and rumination in breast cancer patients: perseveration worsens self-rated health. Journal Of Behavioral Medicine 2020, 44: 253-259. PMID: 33135103, PMCID: PMC8272958, DOI: 10.1007/s10865-020-00192-9.Peer-Reviewed Original ResearchMeSH KeywordsAnxietyBreast NeoplasmsFatigueFemaleHumansPainQuality of LifeSurveys and QuestionnairesConceptsSelf-rated healthBreast cancer patientsBreast Cancer Prevention Trial Symptom ChecklistCancer-related distressBreast cancer symptomsPoor physical functioningPhysical functioningCancer patientsPhysical symptomsAdjuvant treatmentCancer symptomsGreater cancer-related distressHigher cancer-related distressGreater painLower self-rated healthBody mass indexQuality of lifePhysical comorbiditiesMass indexRAND-36Menopause statusCancer stageCancer trajectorySymptom ChecklistSymptomsFeasibility of implementing a text-based symptom-monitoring program of endometrial, ovarian, and breast cancer patients during treatment
Naughton MJ, Salani R, Peng J, Lustberg M, DeGraffinreid C, Moon J, Loyan H, Beverly Hery CM, Paskett ED. Feasibility of implementing a text-based symptom-monitoring program of endometrial, ovarian, and breast cancer patients during treatment. Quality Of Life Research 2020, 30: 3241-3254. PMID: 33052514, PMCID: PMC8528739, DOI: 10.1007/s11136-020-02660-w.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsFatigueFeasibility StudiesFemaleHumansMiddle AgedQuality of LifeSurveys and QuestionnairesConceptsBreast cancer patientsCancer patientsPatient Health QuestionnaireOverall mean ageHealth care teamNon-medical needsNon-Hispanic whitesLay navigatorsPatient navigationMean ageSleep disturbancesCare teamHealth QuestionnaireLow adherencePatient responseAverage adherenceSleep qualitySymptom monitoringBreast patientsPatientsCancer typesMonthly feedbackMonthsGlobal qualitySymptoms
2017
Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data
Orchard T, Andridge R, Yee L, Lustberg M. Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. Journal Of The Academy Of Nutrition And Dietetics 2017, 118: 578-588.e1. PMID: 29233615, PMCID: PMC5869134, DOI: 10.1016/j.jand.2017.09.024.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBreast NeoplasmsCancer SurvivorsCross-Sectional StudiesDietDrug-Related Side Effects and Adverse ReactionsFemaleHumansInflammationInterleukin-17Interleukin-6Middle AgedPilot ProjectsPostmenopauseQuality of LifeReceptors, Tumor Necrosis Factor, Type IITreatment OutcomeConceptsBreast cancer survivorsBody mass indexQuality of lifeLower IL-6Cancer survivorsDiet qualityIL-6Breast cancerTNFR-2QOL measuresEndocrine receptor-positive breast cancerReceptor-positive breast cancerEarly-stage breast cancerMidwestern cancer centerModifiable lifestyle factorsSerum proinflammatory cytokinesCancer Therapy-BreastHealthy Eating IndexAromatase inhibitor treatmentCross-sectional analysisEndocrine subscaleOverall HEIPrior chemotherapyPostmenopausal womenPrimary therapyRandomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain
Lustberg M, Orchard T, Reinbolt R, Andridge R, Pan X, Belury M, Cole R, Logan A, Layman R, Ramaswamy B, Wesolowski R, Berger M, Patterson E, Loprinzi C, Shapiro C, Yee L. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain. Breast Cancer Research And Treatment 2017, 167: 709-718. PMID: 29101597, PMCID: PMC5809189, DOI: 10.1007/s10549-017-4559-z.Peer-Reviewed Original ResearchConceptsQuality of lifeJoint symptomsRandomized placebo-controlled pilot trialBrief Pain Inventory-Short FormPostmenopausal breast cancer patientsRed blood cell (RBC) nPlacebo-controlled pilot trialFACT-ES scoresPlacebo-controlled studyPain severity scoreBreast cancer survivorsBreast cancer patientsAnti-inflammatory propertiesAdjuvant AICommon toxicitiesFACT-ESPurposeAromatase inhibitorsPrimary endpointDrug adherencePill countSecondary outcomesMusculoskeletal painTreatment armsCancer survivorsFatty acids
2014
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Hershman D, Lacchetti C, Dworkin R, Lavoie Smith E, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg M, Paice J, Schneider B, Smith M, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi C. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal Of Clinical Oncology 2014, 32: 1941-1967. PMID: 24733808, DOI: 10.1200/jco.2013.54.0914.Peer-Reviewed Original ResearchMeSH KeywordsAdultAminesAmitriptylineAnalgesicsAnticonvulsantsAntidepressive Agents, TricyclicAntineoplastic AgentsBaclofenComorbidityCyclohexanecarboxylic AcidsDrug Therapy, CombinationDuloxetine HydrochlorideEvidence-Based MedicineGabapentinGamma-Aminobutyric AcidGelsHumansIncidenceKetamineNeoplasmsNeuralgiaPeripheral Nervous System DiseasesQuality of LifeRandomized Controlled Trials as TopicSeverity of Illness IndexSurvivorsThiophenesTreatment OutcomeUnited StatesConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyPrimary outcomePrevention of CIPNTreatment of CIPNClinical Oncology Clinical Practice GuidelineOncology Clinical Practice GuidelineNeuropathic pain conditionsSeverity of neuropathyClinical practice guidelinesPatient-reported outcomesAdult cancer survivorsQuality of lifeSystematic literature searchEvidence-based guidanceDifferent time pointsPain conditionsCancer survivorsTreatment optionsTricyclic antidepressantsPractice guidelinesAdult cancersNeurophysiologic changesEligibility criteriaTreatment approaches
2007
Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer
Lustberg M, Edelman M. Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer. Current Treatment Options In Oncology 2007, 8: 38-46. PMID: 17634834, DOI: 10.1007/s11864-007-0020-6.Peer-Reviewed Original ResearchConceptsPlatinum-based chemotherapyQuality of lifeLung cancerNew agentsAdvanced non-small cell lung cancerOptimal durationNon-small cell lung cancerPlatinum-based combination chemotherapyEpidermal growth factor receptor inhibitorsGrowth factor receptor inhibitorsBenefit of chemotherapyFirst-line chemotherapyAdditional survival benefitAdvanced stage diseaseDuration of therapyMetastatic lung cancerCell lung cancerMatrix metalloproteinase inhibitorsCytotoxic regimenPlatinum doubletsLine chemotherapySequential therapyStage diseaseCombination chemotherapyOverall survival